Poseida Therapeutics Inc Quick Ratio (PSTX) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Poseida Therapeutics Inc   (NASDAQ: PSTX)

Poseida Therapeutics Inc 's Quick Ratio

PSTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Poseida Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Poseida Therapeutics Inc 's Quick Ratio to 3.2, Quick Ratio remained below Poseida Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 86 other companies have achieved higher Quick Ratio than Poseida Therapeutics Inc in third quarter 2024. While Quick Ratio total ranking has improved so far during the Q3 2024 to 752, from total ranking in the second quarter 2024 at 933.

Explain Quick Ratio?
How much Cash & cash equivalents PSTX´s has?
What are PSTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PSTX Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change -6.22 % 93.22 % 61.77 % 32.35 % 57.19 %
Y / Y Cash & cash equivalent Change -3.34 % 10.81 % -19.64 % -24.88 % -14.39 %
Quick Ratio MRQ 3.2 2.47 2.52 2.98 3.1
PSTX's Total Ranking # 752 # 933 # 902 # 897 # 843
Seq. Current Liabilities Change -25.12 % 22.38 % 10.45 % -7.35 % 54.29 %
Seq. Cash & cash equivalent Change -2.93 % 19.72 % -6.39 % -11.15 % 11.29 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 87
Healthcare Sector # 375
Overall Market # 752


Quick Ratio Statistics
High Average Low
271.86 26.43 2.47
(Sep 30 2020)   (Jun 30 2024)




Financial Statements
Poseida Therapeutics Inc 's Current Liabilities $ 72 Millions Visit PSTX's Balance sheet
Poseida Therapeutics Inc 's Cash & cash equivalent $ 231 Millions Visit PSTX's Balance sheet
Source of PSTX's Sales Visit PSTX's Sales by Geography


Cumulative Poseida Therapeutics Inc 's Quick Ratio

PSTX's Quick Ratio for the trailling 12 Months

PSTX Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 38.89 % 60.58 % 44.52 % 32.11 % 30.13 %
Y / Y Cash & cash equivalent TTM Growth -10.54 % -13.27 % -9.14 % 2.85 % 21.17 %
Quick Ratio TTM 2.76 2.74 3.12 3.7 4.29
Total Ranking TTM # 3355 # 3230 # 3317 # 3286 # 3594
Seq. Current Liabilities TTM Growth -1.48 % 16.79 % 12.18 % 7.6 % 13.9 %
Seq. Cash & cash equivalent TTM Growth -0.9 % 2.68 % -5.32 % -7.15 % -3.92 %

Quick ratio ranking by company, industry and sector >> Back to PSTX Financial Strength Comparisons >> Go to Compare PSTX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Poseida Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Poseida Therapeutics Inc 's Quick Ratio to 2.76, Quick Ratio remained below PSTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 149 other companies have achieved higher Quick Ratio than Poseida Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3230 to 3355.

Explain Quick Ratio?
How much Cash & cash equivalents PSTX´s has?
What are PSTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 150
Healthcare Sector # 917
Within the Market # 3355


trailing twelve months Quick Ratio Statistics
High Average Low
8.62 4.98 2.61
(Sep 30 2021)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Vir Biotechnology Inc   8.52 $ 998.555  Millions$ 117.161  Millions
Precision Biosciences Inc  8.45 $ 101.202  Millions$ 11.982  Millions
Qiagen N v   8.43 $ 1,152.992  Millions$ 136.753  Millions
Quince Therapeutics Inc   8.33 $ 45.172  Millions$ 5.425  Millions
Kodiak Sciences Inc   8.22 $ 197.864  Millions$ 24.060  Millions
Iteos Therapeutics Inc   8.20 $ 488.710  Millions$ 59.590  Millions
Repligen Corp  8.15 $ 783.964  Millions$ 96.195  Millions
Cabaletta Bio Inc   8.00 $ 183.012  Millions$ 22.882  Millions
Fate Therapeutics Inc   7.93 $ 296.923  Millions$ 37.422  Millions
Solid Biosciences Inc   7.49 $ 171.117  Millions$ 22.854  Millions
Jasper Therapeutics Inc   7.42 $ 92.502  Millions$ 12.459  Millions
Immunovant Inc   7.10 $ 472.941  Millions$ 66.606  Millions
Caribou Biosciences Inc   7.10 $ 228.178  Millions$ 32.159  Millions
Ginkgo Bioworks Holdings Inc   6.73 $ 616.214  Millions$ 91.533  Millions
Krystal Biotech Inc   6.57 $ 588.324  Millions$ 89.527  Millions
Black Hawk Acquisition Corporation  6.41 $ 0.324  Millions$ 0.051  Millions
Vor Biopharma Inc   6.17 $ 62.809  Millions$ 10.182  Millions
Genenta Science S p a   6.03 $ 14.179  Millions$ 2.351  Millions
Metagenomi Therapeutics Inc   6.01 $ 274.587  Millions$ 45.692  Millions
Molecular Partners Ag  5.92 $ 70.439  Millions$ 11.893  Millions
Monte Rosa Therapeutics Inc   5.82 $ 242.186  Millions$ 41.641  Millions
Beam Therapeutics Inc   5.57 $ 925.757  Millions$ 166.244  Millions
Adverum Biotechnologies Inc   5.54 $ 153.241  Millions$ 27.657  Millions
Fennec Pharmaceuticals Inc   5.42 $ 40.320  Millions$ 7.435  Millions
Black Diamond Therapeutics Inc   5.42 $ 112.682  Millions$ 20.800  Millions
Taysha Gene Therapies Inc   5.38 $ 157.688  Millions$ 29.335  Millions
Springworks Therapeutics Inc   5.33 $ 376.619  Millions$ 70.613  Millions
Compugen Ltd  5.24 $ 103.255  Millions$ 19.712  Millions
Surrozen Inc   5.07 $ 31.012  Millions$ 6.120  Millions
Passage Bio Inc   5.00 $ 84.826  Millions$ 16.951  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.